Dr Zeeshan Khan
Pakistan’s pharmaceutical industry, with more than 700 registered pharmaceutical companies, has quietly reached a landmark that deserves far greater public attention. For the first time in its history, the sector has crossed PKR 1 trillion in annual revenues, reflecting not only its growing economic significance but also its strategic importance for national healthcare, industrial development, and exports. This milestone is more than a financial achievement. It signals a structural transformation in an industry that has long struggled with inflation, currency depreciation, supply chain disruptions, and pricing constraints. The recent deregulation of prices for non-essential medicines has reshaped the financial landscape, allowing pharmaceutical manufacturers to absorb rising production costs while strengthening their ability to invest in research, technology, and expansion.
From a medical professional’s perspective, the industry’s evolution is both encouraging and instructive. A review of trailing twelve-month financial data, fiscal performance, and reports from the Pakistan Credit Rating Agency, Topline Securities, Pakistan Stock Exchange, and IQVIA retail market audits reveals that Pakistan’s pharmaceutical market continues to operate as an oligopoly. Although more than 650 pharmaceutical manufacturers are registered in the country, the top ten companies continue to command an overwhelming share of the market through their established brands, extensive distribution networks, and manufacturing capabilities. One of the most significant catalysts behind the sector’s improved performance has been the government’s decision to deregulate prices for non-essential medicines. For years, pharmaceutical manufacturers struggled to cope with soaring costs of imported raw materials, energy, packaging, and logistics while operating under strict price controls. As inflation accelerated and the Pakistani rupee depreciated, profit margins came under severe pressure.
The deregulation policy has provided much-needed breathing space. Companies can now adjust prices in response to market conditions, allowing them to recover increased production costs. Consequently, gross profit margins among leading listed pharmaceutical companies have expanded from nearly 35 per cent to an average of 41–44 per cent. Stronger profitability has improved cash flows, encouraged investment in manufacturing facilities, enhanced regulatory compliance, and strengthened overall financial stability. Another defining trend is the changing competitive landscape resulting from multinational corporations restructuring or reducing their footprint in Pakistan. Several global pharmaceutical companies have shifted priorities towards asset-light business models and regional restructuring. Rather than weakening the domestic market, this transition has opened new opportunities for well-established local companies.
Pakistani pharmaceutical groups such as AGP Limited, OBS Pakistan, and Lucky Core Industries have actively acquired mature international brands and product portfolios. These acquisitions have enabled local firms to expand therapeutic offerings, strengthen market share, and reduce dependence on foreign ownership. This gradual consolidation reflects increasing confidence in the capabilities of Pakistan’s pharmaceutical sector. Exports have emerged as another powerful growth engine. Pakistan’s pharmaceutical exports have reached a record level, growing by more than 34 per cent to exceed US$450 million annually. Although exports remain relatively small compared with regional competitors, the growth trajectory is highly encouraging.
Leading companies, including Getz Pharma, Ferozsons Laboratories, and BF Biosciences, are increasingly investing in export-oriented production and international regulatory compliance. Expanding into overseas markets not only generates valuable foreign exchange but also provides protection against domestic economic volatility and currency depreciation. Export diversification is becoming essential for sustaining long-term industry growth. Despite these encouraging developments, important challenges remain. Pakistan still imports a substantial proportion of its Active Pharmaceutical Ingredients (APIs), making manufacturers vulnerable to exchange rate fluctuations and global supply chain disruptions. Energy costs, taxation, regulatory delays, and limited investment in pharmaceutical research continue to affect competitiveness.
Moreover, industry growth must never come at the expense of medicine affordability. Policymakers face the delicate responsibility of balancing financial sustainability for manufacturers with equitable access to medicines for patients. Effective regulation, transparent pricing mechanisms, and targeted subsidies for essential medicines will remain critical to achieving this balance. The sector’s long-term success will also depend on greater investment in innovation, biotechnology, local API manufacturing, digital health technologies, and workforce development. Compliance is a major pillar of this transformation. Strengthening quality assurance systems, encouraging research collaborations between academia and industry, and promoting internationally recognised manufacturing standards will position Pakistan as a more competitive pharmaceutical producer globally.
In contrast, India has developed into one of the world’s largest pharmaceutical producers, with an industry worth around US$65–70 billion and pharmaceutical exports exceeding US$27 billion annually. India supplies nearly 20 per cent of the world’s generic medicines by volume and has thousands of manufacturing facilities that meet international regulatory standards. While Pakistan’s market is dominated by a handful of leading companies, India has more than 3,000 pharmaceutical companies and 10,000+ manufacturing units, supported by substantial investment in research, biotechnology, vaccines, and export-oriented manufacturing.
Pakistan’s pharmaceutical industry stands at a defining moment. Crossing the PKR 1 trillion revenue mark represents far more than commercial success—it reflects resilience, adaptation, and growing industrial maturity. If policymakers continue to pursue supportive reforms while ensuring patient protection, and if industry leaders prioritise innovation alongside profitability, Pakistan can transform its pharmaceutical sector into a regional manufacturing and export powerhouse. Nevertheless, the industry still faces significant challenges, including dependence on imported APIs, exchange rate volatility, regulatory requirements, rising energy costs, lower spending on pharmaceutical research and development, and affordability concerns for patients.
In a nutshell, the coming decade offers an opportunity to build a globally competitive pharmaceutical ecosystem that delivers high-quality medicines, generates employment, strengthens exports, and contributes meaningfully to national economic development. The foundations have been laid; the challenge now is to sustain this momentum responsibly.
The writer is a personal finance and financial literacy enthusiast with an investing experience in financial markets. He tweets @DrZeeshanKhanA1
Courtesy
